RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
RenovorX通過市場私募與合格投資者簽署了1110萬美元的最終認購協議
- Cash position now expected to fund current operating plan into 2026
- Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial
- Financing also enables the expansion of RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) clinical development pipeline into additional cancer indications
- 現在預計現金狀況將爲2026年的當前運營計劃提供資金
- 融資爲將正在進行的關鍵的Tiger-Pac第三階段試驗推進到第二次中期讀數和完成試驗提供了現金渠道
- 融資還使RenovorX的TAMP（經動脈微灌注）臨床開發管道擴展到其他癌症適應症
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。